Educational guide
Pharmalot, Pharmalittle: Vertex and Ireland battle over price of cystic fibrosis drug
H ello, everyone, and how are you today? We are just fine, thank you, despite the gloomy clouds hovering over the Pharmalot campus. After all, the glass is half full, even if some believe it is just a stupid glass. In any event, we are forging ahead with plans
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
H ello, everyone, and how are you today? We are just fine, thank you, despite the gloomy clouds hovering over the Pharmalot campus. After all, the glass is half full, even if some believe it is just a stupid glass. In any event, we are forging ahead with plans to talk to interesting people and forage for fascinating items to hold your attention. On that note, we also welcome juicy tips and unredacted documents. Meanwhile, here are some tidbits. Have a grand day and do stay in touch … Ireland’s Health Service Executive and Vertex Pharmaceuticals appear ready to resume talks about the price of the Orkambi cystic fibrosis drug , the Irish Times reports. The National Center for Pharmacoeconomics, the national watchdog agency, says that Orkambi is too expensive at the price demanded by Vertex, which is about $170,000 annually. Hundreds of people have protested outside government offices this week seeking access to the treatment. President-elect Donald Trump is weighing naming a staunch libertarian as the next Food and Drug Administration commissioner , STAT writes. Jim O’Neill, who works for Peter Thiel, the billionaire Trump donor, once called for eliminating the agency mandate to determine whether new medicines are effective before approving them for sale. He is not a physician, and lacks the strong science background most former commissioners have had. STAT+ Exclusive Story Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
Individual plans
Group plans
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe